PMGC Holdings, formerly Elevai Labs, has completed a full-scale pivot from a micro-cap skincare company into a diversified holding company whose center of gravity has shifted to precision aerospace and defense manufacturing. The transformation, executed through a series of acquisitions in 2025 and 2026, has produced a portfolio of four operating subsidiaries generating real revenue, a clinical-stage biotech subsidiary advancing an AI-discovered drug pipeline, and a multi-strategy investment arm, all financed through a web of equity line of credit facilities that carry meaningful dilution risk.
The second quarter produced revenue of $1.3 million, the first meaningful print from the newly assembled manufacturing subsidiaries. The operating loss for the quarter reached nearly $3 million. Cash rose to $18.1 million from $5.4 million at the start of the year, funded by equity line of credit inflows. The accumulated deficit widened, and the company carries a going-concern qualification.
The question the next several quarters resolve is whether the aerospace and defense manufacturing subsidiaries can scale revenue fast enough to fund the corporate overhead and the biotech pipeline, or whether the holding company structure becomes a perpetual consumption machine funded by successive equity issuances.